130 related articles for article (PubMed ID: 10928185)
1. Cyfra 21-1: a serological help for detection of distant metastases in head and neck cancer.
Maass JD; Hoffmann-Fazel A; Goeroegh T; Hoffmann M; Meyer JE; Gottschlich S; Rudert H; Maune S
Anticancer Res; 2000; 20(3B):2241-3. PubMed ID: 10928185
[TBL] [Abstract][Full Text] [Related]
2. Cyfra 21-1 in diagnosis of distant metastases of head and neck carcinoma.
Hoffmann-Fazel A; Hoffmann M; Gottschlich S; Maass JD; Rudert H; Maune S
Anticancer Res; 2003; 23(2A):917-20. PubMed ID: 12820323
[TBL] [Abstract][Full Text] [Related]
3. Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinomas of the head and neck.
Kuropkat C; Lippert BM; Werner JA
Oncology; 2002; 63(3):280-5. PubMed ID: 12381908
[TBL] [Abstract][Full Text] [Related]
4. Cut-off value determination of CYFRA 21-1 for squamous cell carcinomas of the head and neck (SCCHN).
Niemann AM; Goeroegh T; Gottschlich S; Lippert BM; Werner JA
Anticancer Res; 1997; 17(4B):2859-60. PubMed ID: 9329547
[TBL] [Abstract][Full Text] [Related]
5. [Detection of serum soluble fragments of cytokeratins 8 and 18 in patients with squamous epithelial carcinomas of the upper aerodigestive tract].
Maass JD; Niemann AM; Lippert BM; Gottschlich S; Folz BJ; Werner JA
Laryngorhinootologie; 1997 Sep; 76(9):554-8. PubMed ID: 9417185
[TBL] [Abstract][Full Text] [Related]
6. [Study of Cyfra 21-1 as a new tumor marker for the diagnosis of epidermoid carcinoma of the head and neck].
González Sánchez E; López-Ríos Velasco J; Calvo Boizas E; García-Talavera Fernández JR; Martín Ro-dríguez M; Muñoz Herrera A; Del Cañizo Alvarez A
Acta Otorrinolaringol Esp; 1999 Mar; 50(2):85-9. PubMed ID: 10217679
[TBL] [Abstract][Full Text] [Related]
7. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer.
Wollenberg B; Jan V; Schmit UM; Hofmann K; Stieber P; Fateh-Moghadam A
Anticancer Res; 1996; 16(5B):3117-24. PubMed ID: 8920778
[TBL] [Abstract][Full Text] [Related]
8. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma.
Deng YF; Chen P; Lin YZ; Le JZ; Wu XL; Yu MQ; Zhuang PY; Gao MH
J Laryngol Otol; 2003 Mar; 117(3):190-4. PubMed ID: 12648374
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease.
Doweck I; Barak M; Uri N; Greenberg E
Br J Cancer; 2000 Dec; 83(12):1696-701. PubMed ID: 11104568
[TBL] [Abstract][Full Text] [Related]
10. Cyfra 21-1 as a tumor marker for follow-up of patients with squamous cell carcinoma of the oropharynx.
Alkotyfan K; Wiegand S; Müller HH; Windfuhr JP; Werner JA; Sesterhenn AM
Anticancer Res; 2010 Jun; 30(6):2291-6. PubMed ID: 20651382
[TBL] [Abstract][Full Text] [Related]
11. CYFRA 8/18 in head and neck cancer.
Maass JD; Niemann AM; Lippert BM; Gottschlich S; Folz BJ; Werner JA
Anticancer Res; 1999; 19(4A):2699-701. PubMed ID: 10470223
[TBL] [Abstract][Full Text] [Related]
12. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy.
Ebert W; Muley T
Anticancer Res; 1999; 19(4A):2669-72. PubMed ID: 10470217
[TBL] [Abstract][Full Text] [Related]
13. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma.
Kuropkat C; Werner JA
J Laryngol Otol; 2003 Dec; 117(12):1007-8; author reply 1008-9. PubMed ID: 14738621
[No Abstract] [Full Text] [Related]
14. The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck.
Inal E; Laçin M; Asal K; Ceylan A; Köybaşioğlu A; Ileri F; Uslu SS
Kulak Burun Bogaz Ihtis Derg; 2004; 12(1-2):23-30. PubMed ID: 16010093
[TBL] [Abstract][Full Text] [Related]
15. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
16. Clinical usefulness of CYFRA 21-1 for esophageal squamous cell carcinoma in radiation therapy.
Wakatsuki M; Suzuki Y; Nakamoto S; Ohno T; Ishikawa H; Kiyohara H; Kiyozuka M; Shirai K; Nakayama Y; Nakano T
J Gastroenterol Hepatol; 2007 May; 22(5):715-9. PubMed ID: 17444861
[TBL] [Abstract][Full Text] [Related]
17. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma.
Zhong LP; Zhu HG; Zhang CP; Chen WT; Zhang ZY
Int J Oral Maxillofac Surg; 2007 Mar; 36(3):230-4. PubMed ID: 16965897
[TBL] [Abstract][Full Text] [Related]
18. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
19. Cyfra 21-1 as a serum tumor marker for follow-up of patients with laryngeal and hypopharyngeal squamous cell carcinoma.
Al-Shagahin H; Alkotyfan K; Müller HH; Sesterhenn AM; Werner JA
Anticancer Res; 2009 Aug; 29(8):3421-5. PubMed ID: 19661367
[TBL] [Abstract][Full Text] [Related]
20. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
